ERC announces publication of positive data on the efficacy of sitoiganap in patients with recurrent glioblastoma
ISNES, Belgium, June 30, 2022 (GLOBE NEWSWIRE) — ERC Belgium SA (ERC), announced the publication of its most recent efficacy data in the May 2022 edition of Frontiers in oncology. The authors reported remarkable efficacy and safety of a therapeutic vaccine SITOIGANAP administered to 21 patients with recurrent glioblastoma (rGBM). Glioblastoma has a poor prognosis, with half of rGBM patients dying within 8 months of disease recurrence. Data presented by the authors show that treatment with Sitoiganap (also known as Gliovac or ERC1671) more than doubles median overall survival to 19.6 months. This is an unprecedented level of efficacy for a disease for which new therapies have shown no improvement over the past twenty years.
Compared to historical controls, where the majority of patients succumb to rGBM within one year and 2-year survival is extremely rare, the current study reported a 1-year survival of 61% of patients treated with Sitoiganap and a 2-year survival was 45%. Equally important was the observation that Sitoiganap treatments were well tolerated with minimal toxicity compared to the current treatment.
Corresponding author, Daniela Bota, MD, PhD, commented, “These results for Sitoiganap in rGBM represent the most promising answers ever seen. We are delighted to accelerate the clinical development of Sitoiganap. Dr. Bota is Associate Dean for Clinical Research at the UCI School of Medicine and Team Leader of the Comprehensive Brain Tumor Program at UCI Health.
Apostolos Stathopoulos, MD, Ph.D., President and CEO of ERC Belgium, said, “We are delighted that patients with rGBM finally have access to a therapy that allows them to prolong their survival. Equally exciting is that we are seeing improvements in functionality and quality of life in many patients who have responded to treatment. We are now able to confidently move forward with the company’s clinical trial plans for the United States, as well as other treatment approaches that include the right to try and pathways compassionate use, expanded access options and more, which are taking place in many countries around the world.
About Sitoiganap / Gliovac / ERC 1671
Sitoiganap is an advanced immunotherapy derived from brain tumor tissue that is surgically removed from patients with rGBM. This tumor tissue is then processed to obtain inactivated intact cells and ruptured lysed cells from different patients. For treatment, each patient receives repeated intradermal injections of this material (autologous component), as well as the same material derived from three other different cancer patients (allogeneic component). This complex mixture of own and foreign material serves as a potent stimulant of the patient’s immune system and mounts a reactive immune response against residual tumor cells, leading to their destruction.
Sitoiganap is for patients with grade IV glioma (glioblastoma and gliosarcoma) when all other traditional treatments have failed. The indication for Sitoiganap is independent of the genomic profile of the tumour; due to the complex composition of the vaccine, the immune response it triggers targets a wide variety of tumor epitopes and minimizes the development of resistance to treatments. In the United States, the vaccine is currently in a randomized, placebo-controlled Phase 2 clinical trial as part of a combination treatment for recurrent glioblastoma and gliosarcoma.
About the REB
Epitopoietic Research Corporation (ERC-Belgium SA) is an emerging clinical-stage biopharmaceutical company developing a safe and highly effective approach to the treatment of cancer, particularly brain cancers. The company’s headquarters are based in Belgium, with subsidiaries in the United States, the Netherlands, Canada and Australia, as well as an international presence worldwide and country-specific agreements in Europe and in Latin America. ERC has assembled a network of leading neuro-oncologists in many countries to propel its immunotherapies into clinical development and into market. While the company’s vaccine has shown great promise in patients with recurrent glioblastoma, this therapeutic approach can be seen as a platform application, as it could potentially be applicable to many other types of hard-to-treat cancers. . As such, it has the potential to bring new hope to patients with otherwise bleak prognoses.
To learn more, please visit http://erc-immunotherapy.com.
JQA Partners, Inc.